Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;9(5):997-1007.
doi: 10.1016/j.molonc.2014.07.025. Epub 2014 Aug 14.

Early phase clinical trials to identify optimal dosing and safety

Natalie Cook  1 , Aaron R Hansen  1 , Lillian L Siu  2 , Albiruni R Abdul Razak  1
Affiliations
Review

Early phase clinical trials to identify optimal dosing and safety

Natalie Cook et al. Mol Oncol. 2015 May.

Abstract

The purpose of early stage clinical trials is to determine the recommended dose and toxicity profile of an investigational agent or multi-drug combination. Molecularly targeted agents (MTAs) and immunotherapies have distinct toxicities from chemotherapies that are often not dose dependent and can lead to chronic and sometimes unpredictable side effects. Therefore utilizing a dose escalation method that has toxicity based endpoints may not be as appropriate for determination of recommended dose, and alternative parameters such as pharmacokinetic or pharmacodynamic outcomes are potentially appealing options. Approaches to enhance safety and optimize dosing include improved preclinical models and assessment, innovative model based design and dose escalation strategies, patient selection, the use of expansion cohorts and extended toxicity assessments. Tailoring the design of phase I trials by adopting new strategies to address the different properties of MTAs is required to enhance the development of these agents. This review will focus on the limitations to safety and dose determination that have occurred in the development of MTAs and immunotherapies. In addition, strategies are proposed to overcome these challenges to develop phase I trials that can more accurately define the recommended dose and identify adverse events.

Keywords: Phase I trials; Recommended phase 2 dose; Toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Elements of a dose escalation study.
See this image and copyright information in PMC

References

    1. Agoram, B.M. , 2009. Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br. J. Clin. Pharmacol. 67, 153–160. - PMC - PubMed
    1. Agrawal, N. , Frederick, M.J. , Pickering, C.R. , Bettegowda, C. , Chang, K. , Li, R.J. , Fakhry, C. , Xie, T.X. , Zhang, J. , Wang, J. , Zhang, N. , El-Naggar, A.K. , Jasser, S.A. , Weinstein, J.N. , Trevino, L. , Drummond, J.A. , Muzny, D.M. , Wu, Y. , Wood, L.D. , Hruban, R.H. , Westra, W.H. , Koch, W.M. , Califano, J.A. , Gibbs, R.A. , Sidransky, D. , Vogelstein, B. , Velculescu, V.E. , Papadopoulos, N. , Wheeler, D.A. , Kinzler, K.W. , Myers, J.N. , 2011. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 333, 1154–1157. - PMC - PubMed
    1. Arnheiter, H. , Frese, M. , Kambadur, R. , Meier, E. , Haller, O. , 1996. Mx transgenic mice–animal models of health. Curr. Top. Microbiol. Immunol. 206, 119–147. - PubMed
    1. Babb, J. , Rogatko, A. , Zacks, S. , 1998. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 17, 1103–1120. - PubMed
    1. Bedard, P.L. , Hansen, A.R. , Ratain, M.J. , Siu, L.L. , 2013. Tumour heterogeneity in the clinic. Nature. 501, 355–364. - PMC - PubMed

MeSH terms

Substances